[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338208-105":59,"doc-detail-338208-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","developing-vaccines-in-pancreatic-adenocarcinoma-trials-and-tribulations","Developing Vaccines in Pancreatic Adenocarcinoma - Trials and Tribulations","","Pancreatic adenocarcinoma remains among the most difficult cancers to treat, with poor survival despite major advances in therapy. Immunotherapy, especially vaccines, is increasingly viewed as a way to engage the immune system against aggressive disease. This review examines the key obstacles in developing pancreatic adenocarcinoma vaccine strategies, including an immunosuppressive tumor microenvironment, heterogeneous tumor antigens, and incomplete knowledge of immune-evasion mechanisms. It surveys peptide-, dendritic cell-, and viral vector-based vaccines, highlights the difficulty of translating preclinical success to clinical benefit, and evaluates emerging mRNA vaccine opportunities, challenges, and potential applications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/developing-vaccines-in-pancreatic-adenocarcinoma-trials-and-tribulations/338208/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/developing-vaccines-in-pancreatic-adenocarcinoma-trials-and-tribulations/338208.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are vaccines difficult to develop for pancreatic adenocarcinoma?","Question",{"text":112,"@type":113},"Key barriers include the immunosuppressive tumor microenvironment, tumor antigen heterogeneity, and limited understanding of immune-evasion mechanisms used by pancreatic cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which vaccine platforms have been explored for pancreatic adenocarcinoma?",{"text":117,"@type":113},"Peptide-based, dendritic cell-based, and viral vector-based vaccines have been tested across preclinical and clinical settings.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenge exists when translating vaccine results from models to patients?",{"text":121,"@type":113},"Promising preclinical outcomes have often failed to translate into clear clinical efficacy in humans.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338208,1790190871,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nDeveloping Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations  \nThuy Phan 1, Darrell Fan 2 and Laleh G. Melstrom 2, *  \nCitation: Phan, T.; Fan, D.; Melstrom, L.G. Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations. Curr. Oncol. 2024, 31, 4855–4884. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol31090361  \nReceived: 19 June 2024  \nRevised: 13 August 2024  \nAccepted: 21 August 2024  \nPublished: 23 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA; [thuyphan@coh.org](thuyphan@coh.org)  \n2 Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA; [dfan@coh.org](dfan@coh.org)  \n* Correspondence: [lmelstrom@coh.org](lmelstrom@coh.org)  \nAbstract: Pancreatic adenocarcinoma represents one of the most challenging malignancies to treat, with dismal survival rates despite advances in therapeutic modalities. Immunotherapy, particularly vaccines, has emerged as a promising strategy to harness the body’s immune system in combating this aggressive cancer. This abstract reviews the trials and tribulations encountered in the development of vaccines targeting pancreatic adenocarcinoma. Key challenges include the immunosuppressive tumor microenvironment, the heterogeneity of tumor antigens, and a limited understanding of immune evasion mechanisms employed by pancreatic cancer cells. Various vaccine platforms, including peptide-based, dendritic cell-based, and viral vector-based vaccines, have been explored in preclinical and clinical settings. However, translating promising results from preclinical models to clinical efficacy has proven elusive. In recent years, mRNA vaccines have emerged as a promising immunotherapeutic strategy in the fight against various cancers, including pancreatic adenocarcinoma. We will discuss the potential applications, opportunities, and challenges associated with mRNA vaccines in pancreatic cancer treatment.  \nKeywords: pancreatic cancer; vaccine; mRNA; neoantigens  \n1. Introduction  \nPancreatic ductal adenocarcinoma (PDAC) stands as a major cause of cancer-related death, with approximately 60,430 new diagnoses recorded in the US in 2021 [1] . This trajectory is projected to increase by 0.5–1% annually, positioning pancreatic cancer asthe second leading cause of cancer-related death in the US by 2030 [1] . As of 2020, the 5-year survival rate remains at only 10%[1] . Notably, most PDAC patients present with no specific early-stage symptoms, hindering early prognosis and treatment interventions. The primary treatment for PDAC involves chemotherapy and surgery, yet only 20% of PDAC patients qualify for surgical intervention upon diagnosis [2] . For patients undergoing tumor resection, an estimated 80% will present with local recurrences within 2 years after surgery [3] . For patients with locally advanced or metastatic pancreatic cancer, the current treatment includes systemic chemotherapy, such as gemcitabine with nab-paclitaxeland FOLFIRINOX (combination of fluorouracil, oxaliplatin, irinotecan, and leucovorin) . Although these regimens contribute to prolonged survival, patients experience enduring challenges of long-term toxicity, compromised quality of life, and ultimately develop drug resistance [4] . Other therapeutic strategies, such as radiation, targeted therapies, and immunotherapies, have been tested on this patient population, but their efficacies remain limited [5,6] . Overall, PDAC presents a formidable challenge with poor long-term survival rates, necessitating the development of n","cbCaib3DNdvwZodq","https://ap.wps.com/l/cbCaib3DNdvwZodq","pdf",2425309,"English","# Abstract\n# Introduction\n# Conventional Pancreatic Cancer Vaccines","[{\"question\":\"Why are vaccines difficult to develop for pancreatic adenocarcinoma?\",\"answer\":\"Key barriers include the immunosuppressive tumor microenvironment, tumor antigen heterogeneity, and limited understanding of immune-evasion mechanisms used by pancreatic cancer cells.\"},{\"question\":\"Which vaccine platforms have been explored for pancreatic adenocarcinoma?\",\"answer\":\"Peptide-based, dendritic cell-based, and viral vector-based vaccines have been tested across preclinical and clinical settings.\"},{\"question\":\"What challenge exists when translating vaccine results from models to patients?\",\"answer\":\"Promising preclinical outcomes have often failed to translate into clear clinical efficacy in humans.\"}]","Developing Vaccines in Pancreatic Adenocarcinoma - Trials and Tribulations | PDF",1790022534,76,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e4375a13aeb1f32d99ba70dc94eb274.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54206bf5ca1d6e79ba40846d21c53a6b.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/748ffef01e5d0630242fdaa7014aa9ba.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d395886f8d0a4c2a0b0d1a8d3d98268.webp",980,1385]